Analysing compliance with calcium and vitamin D supplementations in cancer patients receiving bone resorptive agents

ObjectiveTo assess patient-reported compliance with calcium and vitamin D supplementation and identify barriers in oncology patients prescribed bone resorptive therapy.MethodsA multicentre observational study was conducted across several private day oncology infusion units within Australia. Adult cancer patients receiving denosumab, pamidronate, or zoledronic acid were identified. Eligible patients (excluding those with pre-existing osteoporosis or hypercalcaemia of malignancy) completed a 13-item survey including the MMAS-8 adherence scale. Clinical data were extracted from the CHARM prescribing system. Descriptive and comparative analyses were performed.Results80 people participated. 45% were reported being prescribed calcium and vitamin D supplements; 46.25% denied supplementation and 9% were unsure. Among prescribed patients, the mean MMAS-8 score was 6.86, indicating medium adherence. Hypocalcaemia occurred in 27.5% of patients, 60% of whom reported no supplementation. Vitamin D levels were unavailable in 55% of cases.ConclusionUnder-prescribing and poor monitoring of calcium and vitamin D supplements are prevalent. Systematic supplementation protocols and pharmacist-led education could improve adherence and reduce skeletal-related complications.